Brokerages predict that Five Prime Therapeutics, Inc. (NASDAQ:FPRX) will announce earnings per share (EPS) of ($1.18) for the current quarter, Zacks reports. Two analysts have made estimates for Five Prime Therapeutics’ earnings, with estimates ranging from ($1.28) to ($0.98). Five Prime Therapeutics reported earnings per share of ($0.49) in the same quarter last year, which suggests a negative year-over-year growth rate of 140.8%. The firm is expected to announce its next earnings report on Thursday, August 3rd.
According to Zacks, analysts expect that Five Prime Therapeutics will report full year earnings of ($4.68) per share for the current fiscal year, with EPS estimates ranging from ($4.91) to ($4.26). For the next year, analysts anticipate that the business will post earnings of ($4.97) per share, with EPS estimates ranging from ($6.00) to ($3.56). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side analysts that cover Five Prime Therapeutics.
Five Prime Therapeutics (NASDAQ:FPRX) last announced its earnings results on Thursday, May 4th. The biotechnology company reported ($1.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.96) by $0.25. The firm had revenue of $10.13 million during the quarter, compared to analysts’ expectations of $6.05 million. Five Prime Therapeutics had a negative net margin of 250.98% and a negative return on equity of 21.81%. The firm’s revenue for the quarter was up 55.8% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.49) EPS.
A number of equities analysts have weighed in on the stock. Jefferies Group LLC reaffirmed a “buy” rating and set a $55.00 price target on shares of Five Prime Therapeutics in a research note on Thursday, June 8th. ValuEngine raised shares of Five Prime Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Friday, June 2nd. Zacks Investment Research downgraded shares of Five Prime Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, May 2nd. Cowen and Company started coverage on shares of Five Prime Therapeutics in a report on Friday, March 24th. They set an “outperform” rating for the company. Finally, TheStreet lowered shares of Five Prime Therapeutics from a “c” rating to a “d+” rating in a report on Monday, March 20th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $60.83.
Shares of Five Prime Therapeutics (NASDAQ FPRX) traded up 5.040% during mid-day trading on Tuesday, reaching $30.325. The company’s stock had a trading volume of 92,433 shares. The firm’s 50 day moving average price is $29.90 and its 200-day moving average price is $40.23. The company’s market capitalization is $845.98 million. Five Prime Therapeutics has a 1-year low of $26.65 and a 1-year high of $60.98.
A number of hedge funds and other institutional investors have recently made changes to their positions in FPRX. Dimensional Fund Advisors LP raised its position in shares of Five Prime Therapeutics by 12.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 841,072 shares of the biotechnology company’s stock valued at $42,147,000 after buying an additional 93,211 shares in the last quarter. Teachers Advisors LLC raised its position in Five Prime Therapeutics by 0.7% in the fourth quarter. Teachers Advisors LLC now owns 238,428 shares of the biotechnology company’s stock valued at $11,948,000 after buying an additional 1,558 shares during the period. Creative Planning raised its position in Five Prime Therapeutics by 42.6% in the first quarter. Creative Planning now owns 6,690 shares of the biotechnology company’s stock valued at $242,000 after buying an additional 2,000 shares during the period. Advisory Research Inc. acquired a new position in Five Prime Therapeutics during the fourth quarter valued at approximately $1,367,000. Finally, Adams Diversified Equity Fund Inc. raised its position in Five Prime Therapeutics by 56.3% in the first quarter. Adams Diversified Equity Fund Inc. now owns 18,600 shares of the biotechnology company’s stock valued at $672,000 after buying an additional 6,700 shares during the period. 86.01% of the stock is owned by institutional investors.
TRADEMARK VIOLATION NOTICE: This report was originally reported by Stock Observer and is owned by of Stock Observer. If you are accessing this report on another site, it was stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this report can be accessed at https://www.thestockobserver.com/2017/06/20/1-18-eps-expected-for-five-prime-therapeutics-inc-fprx-this-quarter.html.
About Five Prime Therapeutics
Five Prime Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Five Prime Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.